In the Spotlight - Large pharmaceutical firms are looking hard at buying smaller, younger biotech and pharma companies and are willing to part with big bucks to swing the deals. J&J's (USD)2.4 billion acquisition of Scios epitomizes the trend. The objective: Add products to the pipeline at a time when the buyer's own R&D efforts are slow in paying off.
Year of publication:
Mergers & acquisitions. - New York, NY : Investment Dealers' Digest, ISSN 0026-0010, ZDB-ID 8628555. - Vol. 38.2003, 4, p. 16